Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 484963, 21 pages
http://dx.doi.org/10.1155/2015/484963
Review Article

Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy

Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, 7 York Road, Parktown, Johannesburg 2193, South Africa

Received 2 December 2014; Revised 8 May 2015; Accepted 10 May 2015

Academic Editor: Eberval G. Figueiredo

Copyright © 2015 Famida G. Hoosain et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Löscher and H. Potschka, “Drug resistance in brain diseases and the role of drug efflux transporters,” Nature Reviews Neuroscience, vol. 6, no. 8, pp. 591–602, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Nassar, A. Rom, A. Nyska, and S. Benita, “Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug,” Journal of Controlled Release, vol. 133, no. 1, pp. 77–84, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Takano, R. Yumoto, and T. Murakami, “Expression and function of efflux drug transporters in the intestine,” Pharmacology and Therapeutics, vol. 109, no. 1-2, pp. 137–161, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. P. H. Elsinga, N. H. Hendrikse, J. Bart, W. Vaalburg, and A. van Waarde, “PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS,” Current Pharmaceutical Design, vol. 10, no. 13, pp. 1493–1503, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. E. M. Taylor, “The impact of efflux transporters in the brain on the development of drugs for CNS disorders,” Clinical Pharmacokinetics, vol. 41, no. 2, pp. 81–92, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. K. de van Wetering, A. Burkon, W. Feddema et al., “Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol,” Molecular Pharmacology, vol. 75, no. 4, pp. 876–885, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Demeule, A. Régina, J. Jodoin et al., “Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier,” Vascular Pharmacology, vol. 38, no. 6, pp. 339–348, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Lalatsa, A. G. Schätzlein, and I. F. Uchegbu, “Drug delivery across the blood-brain barrier,” Current Drug Delivery, vol. 5, no. 50, pp. 657–666, 2011. View at Google Scholar
  9. A. L. Bartels, R. Kortekaas, J. Bart et al., “Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration,” Neurobiology of Aging, vol. 30, no. 11, pp. 1818–1824, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. Y.-C. Lin, V. L. Ellingrod, J. R. Bishop, and D. D. Miller, “The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia,” Therapeutic Drug Monitoring, vol. 28, no. 5, pp. 668–672, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. H. B. Stolp and K. M. Dziegielewska, “Review: role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases,” Neuropathology and Applied Neurobiology, vol. 35, no. 2, pp. 132–146, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. D. J. Roberts and K. B. Goralski, “A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain,” Expert Opinion on Drug Metabolism and Toxicology, vol. 4, no. 10, pp. 1245–1264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. L. Bartels, A. T. M. Willemsen, R. Kortekaas et al., “Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA,” Journal of Neural Transmission, vol. 115, no. 7, pp. 1001–1009, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. van Os, G. Kenis, and B. P. F. Rutten, “The environment and schizophrenia,” Nature, vol. 468, no. 7321, pp. 203–212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Pharoah, J. J. Mari, J. Rathbone, and W. Wong, “Family intervention for schizophrenia,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD000088, 2006. View at Google Scholar · View at Scopus
  16. C. U. Nnadi and A. K. Malhotra, “Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics,” Current Psychiatry Reports, vol. 9, no. 4, pp. 313–318, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC, USA, 4th edition, 1994.
  18. P. Kulhara, P. Kulhara, S. Chakrabarti, and S. Chakrabarti, “Culture and schizophrenia and other psychotic disorders,” Psychiatric Clinics of North America, vol. 24, no. 3, pp. 449–464, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. N. A. Khin, Y.-F. Chen, Y. Yang, P. Yang, and T. P. Laughren, “Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration,” Journal of Clinical Psychiatry, vol. 73, no. 6, pp. 856–864, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. D. G. Kingdon, K. Ashcroft, B. Bhandari et al., “Schizophrenia and borderline personality disorder: similarities and differences in the experience of auditory hallucinations, paranoia, and childhood trauma,” Journal of Nervous and Mental Disease, vol. 198, no. 6, pp. 399–403, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Falkai and H.-J. Möller, “Neurobiology of schizophrenia: from outcome to pathophysiological insights,” European Archives of Psychiatry and Clinical Neuroscience, vol. 262, no. 2, pp. 93–94, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. T. R. Insel, “Rethinking schizophrenia,” Nature, vol. 468, no. 7321, pp. 187–193, 2010. View at Publisher · View at Google Scholar
  23. R. Tandon, H. A. Nasrallah, and M. S. Keshavan, “Schizophrenia, ‘just the facts’ 4. Clinical features and conceptualization,” Schizophrenia Research, vol. 110, no. 1–3, pp. 1–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Bebawy and M. Chetty, “Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia,” BioEssays, vol. 3, no. 2, pp. 183–188, 2008. View at Publisher · View at Google Scholar
  25. D. W. Boulton, C. L. DeVane, H. L. Liston, and J. S. Markowitz, “In vitro P-glycoprotein affinity for atypical and conventional antipsychotics,” Life Sciences, vol. 71, no. 2, pp. 163–169, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. A. A. El Ela, S. Härtter, U. Schmitt, C. Hiemke, H. Spahn-Langguth, and P. Langguth, “Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds—implications for pharmacokinetics of selected substrates,” Journal of Pharmacy and Pharmacology, vol. 56, no. 8, pp. 967–975, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. U. Schmitt, A. Abou El-Ela, L. J. Guo et al., “Cyclosporine a (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp),” Journal of Neural Transmission, vol. 113, no. 7, pp. 787–801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. K. S. Pang, “Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes (for the gillette review series),” Drug Metabolism & Disposition, vol. 31, no. 12, pp. 1507–1519, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. A. El-Kattan and M. Varma, “Oral absorption, intestinal metabolism and human oral bioavailability,” in Topics on Drug Metabolism, pp. 1–34, Pharmacokinetics, Dynamics and Metabolism Department, Pfizer, New York, NY, USA, 2012. View at Google Scholar
  30. A. Schlessinger, N. Khuri, K. M. Giacomini, and A. Sali, “Molecular modeling and ligand docking for solute carrier (SLC) transporters,” Current Topics in Medicinal Chemistry, vol. 13, no. 7, pp. 843–856, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Wagner, H. Spahn-Langguth, A. Hanafy, A. Koggel, and P. Langguth, “Intestinal drug efflux: formulation and food effects,” Advanced Drug Delivery Reviews, vol. 50, no. 1, pp. S13–S31, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. I. P. Kaur, R. Bhandari, S. Bhandari, and V. Kakkar, “Potential of solid lipid nanoparticles in brain targeting,” Journal of Controlled Release, vol. 127, no. 2, pp. 97–109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. B. T. Hawkins and T. P. Davis, “The blood-brain barrier/neurovascular unit in health and disease,” Pharmacological Reviews, vol. 57, no. 2, pp. 173–185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. W. Löscher and H. Potschka, “Blood-brain barrier active efflux transporters: ATP-binding cassette gene family,” NeuroRx, vol. 2, no. 1, pp. 86–98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Löscher and H. Potschka, “Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases,” Progress in Neurobiology, vol. 76, no. 1, pp. 22–76, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Lee, S. Dallas, M. Hong, and R. Bendayan, “Drug transporters in the central nervous system: Brain barriers and brain parenchyma considerations,” Pharmacological Reviews, vol. 53, no. 4, pp. 569–596, 2001. View at Google Scholar · View at Scopus
  37. A. Misra, S. Ganesh, A. Shahiwala, and S. P. Shah, “Drug delivery to the central nervous system: a review,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 6, no. 2, pp. 252–273, 2003. View at Google Scholar · View at Scopus
  38. J.-M. Scherrmann, “Drug delivery to brain via the blood-brain barrier,” Vascular Pharmacology, vol. 38, no. 6, pp. 349–354, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. C. La Fougère, G. Böning, H. Bartmann et al., “Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar,” NeuroImage, vol. 49, no. 2, pp. 1406–1415, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. H. Schinkel, “P-Glycoprotein, a gatekeeper in the blood-brain barrier,” Advanced Drug Delivery Reviews, vol. 36, no. 2-3, pp. 179–194, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. S. G. Aller, J. Yu, A. Ward et al., “Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding,” Science, vol. 323, no. 5922, pp. 1718–1722, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. D. S. Miller, B. Bauer, and A. M. S. Hartz, “Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve CNS pharmacotherapy,” Pharmacological Reviews, vol. 60, no. 2, pp. 196–209, 2008. View at Publisher · View at Google Scholar
  43. R. Gabathuler, “Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases,” Neurobiology of Disease, vol. 37, no. 1, pp. 48–57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Matsson, J. M. Pedersen, U. Norinder, C. A. S. Bergström, and P. Artursson, “Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs,” Pharmaceutical Research, vol. 26, no. 8, pp. 1816–1831, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. V. S. Varma, Y. Ashokraj, C. S. Dey, and R. Panchagnula, “P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement,” Pharmacological Research, vol. 48, no. 4, pp. 347–359, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. M. F. Rosenberg, A. B. Kamis, R. Callaghan, C. F. Higgins, and R. C. Ford, “Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding,” Journal of Biological Chemistry, vol. 278, no. 10, pp. 8294–8299, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Aouali, L. Eddabra, J. Macadré, and H. Morjani, “Immunosuppressors and reversion of multidrug-resistance,” Critical Reviews in Oncology/Hematology, vol. 56, no. 1, pp. 61–70, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. F. J. Sharom, “Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: Its role in modulating protein function,” Frontiers in Oncology, vol. 4, Article ID Article 41, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. O. Fardel, V. Lecureur, and A. Guillouzo, “The P-glycoprotein multidrug transporter,” General Pharmacology: The Vascular System, vol. 27, no. 8, pp. 1283–1291, 1996. View at Publisher · View at Google Scholar · View at Scopus
  50. P. P. Constantinides and K. M. Wasan, “Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: In vitro/in vivo case studies,” Journal of Pharmaceutical Sciences, vol. 96, no. 2, pp. 235–248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. C. F. Higgins and M. M. Gottesman, “Is the multidrug transporter a flippase?” Trends in Biochemical Sciences, vol. 17, no. 1, pp. 18–21, 1992. View at Publisher · View at Google Scholar · View at Scopus
  52. Z. E. Sauna, M. M. Smith, M. Müller, K. M. Kerr, and S. V. Ambudkar, “The mechanism of action of multidrug-resistance-linked P-glycoprotein,” Journal of Bioenergetics and Biomembranes, vol. 33, no. 6, pp. 481–491, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. J.-S. Wang, H.-J. Zhu, J. L. Donovan et al., “Aripiprazole brain concentration is altered in P-glycoprotein deficient mice,” Schizophrenia Research, vol. 110, no. 1-3, pp. 90–94, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. O. L. de Klerk, A. T. M. Willemsen, F. J. Bosker et al., “Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [11C] verapamil as a probe for P-glycoprotein function,” Psychiatry Research—Neuroimaging, vol. 183, no. 2, pp. 151–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. J.-S. Wang, Y. Ruan, R. M. Taylor, J. L. Donovan, J. S. Markowitz, and C. L. DeVane, “The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein,” International Journal of Neuropsychopharmacology, vol. 7, no. 4, pp. 415–419, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Nakagami, N. Yasui-Furukori, M. Saito, T. Tateishi, and S. Kaneo, “Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition,” Clinical Pharmacology and Therapeutics, vol. 78, no. 1, pp. 43–51, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. K. M. Kirschbaum, S. Henken, C. Hiemke, and U. Schmitt, “Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice,” Behavioural Brain Research, vol. 188, no. 2, pp. 298–303, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. B. Feng, J. B. Mills, R. E. Davidson et al., “In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system,” Drug Metabolism and Disposition, vol. 36, no. 2, pp. 268–275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Doran, R. S. Obach, B. J. Smith et al., “The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model,” Drug Metabolism and Disposition, vol. 33, no. 1, pp. 165–174, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. S. A. Hitchcock, “Structural modifications that alter the P-glycoprotein efflux properties of compounds,” Journal of Medicinal Chemistry, vol. 55, no. 11, pp. 4877–4895, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Gohel, S. Modi, K. G. Vyas, and K. S. Rajesh, “Delivery approaches to bypass P-glycoprotein efflux pump,” Pharmaceutical Information, vol. 9, p. 1, 2011. View at Google Scholar
  62. R. Nieto Montesinos, A. Béduneau, Y. Pellequer, and A. Lamprecht, “Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes,” Journal of Controlled Release, vol. 161, no. 1, pp. 50–61, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. E. F. Choo, D. Kurnik, M. Muszkat et al., “Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier,” Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 3, pp. 1012–1018, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Werle and A. Bemkop-Schnürch, “Thiolated chitosans: useful excipients for oral drug delivery,” Journal of Pharmacy and Pharmacology, vol. 60, no. 3, pp. 273–281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. R. L. Hunter, J. McNicholl, and A. A. Lal, “Mechanisms of action of nonionic block copolymer adjuvants,” AIDS Research and Human Retroviruses, vol. 10, no. 2, pp. 95–98, 1994. View at Google Scholar · View at Scopus
  66. M. Werle, “Natural and synthetic polymers as inhibitors of drug efflux pumps,” Pharmaceutical Research, vol. 25, no. 3, pp. 500–511, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. Q. Shen, Y. Lin, T. Handa et al., “Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies,” International Journal of Pharmaceutics, vol. 313, no. 1-2, pp. 49–56, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. E. D. Hugger, K. L. Audus, and R. T. Borchardt, “Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers,” Journal of Pharmaceutical Sciences, vol. 91, no. 9, pp. 1980–1990, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. B. M. Johnson, W. N. Charman, and C. J. H. Porter, “An in vitro examination of the impact of polyethylene glycol 400, pluronic p85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on p-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine,” The AAPS Journal, vol. 4, no. 4, pp. 193–205, 2002. View at Google Scholar · View at Scopus
  70. E. V. Batrakova, S. Li, S. V. Vinogradov, V. Y. Alakhov, D. W. Miller, and A. V. Kabanov, “Mechanism of pluronic effect on P-glycoprotein efflux system in blood brain barrier: contributions of energy depletion and membrane fluidization,” Journal of Pharmacology and Experimental Therapeutics, vol. 299, no. 2, pp. 483–493, 2001. View at Google Scholar · View at Scopus
  71. E. V. Batrakova, D. W. Miller, S. Li, V. Y. Alakhov, A. V. Kabanov, and W. F. Elmquist, “Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies,” The Journal of Pharmacology and Experimental Therapeutics, vol. 296, no. 2, pp. 551–557, 2001. View at Google Scholar · View at Scopus
  72. J. Iqbal, J. Hombach, B. Matuszczak, and A. Bernkop-Schnürch, “Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor,” Journal of Controlled Release, vol. 147, no. 1, pp. 62–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. E. V. Batrakova, S. Li, Y. Li, V. Y. Alakhov, and A. V. Kabanov, “Effect of pluronic P85 on ATPase activity of drug efflux transporters,” Pharmaceutical Research, vol. 21, no. 12, pp. 2226–2233, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. V. Saxena and M. D. Hussain, “Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer,” International Journal of Nanomedicine, vol. 7, pp. 713–721, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Werle and M. Hoffer, “Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine,” Journal of Controlled Release, vol. 111, no. 1-2, pp. 41–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Bernkop-Schnurch, M. Hornof, and T. Zoidl, “Thiolated polymers—thiomers: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates,” International Journal of Pharmaceutics, vol. 260, no. 2, pp. 229–237, 2003. View at Publisher · View at Google Scholar
  77. T. Bansal, N. Akhtar, M. Jaggi, R. K. Khar, and S. Talegaonkar, “Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation,” Drug Discovery Today, vol. 14, no. 21-22, pp. 1067–1074, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. B. D. Rege, J. P. Y. Kao, and J. E. Polli, “Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers,” European Journal of Pharmaceutical Sciences, vol. 16, no. 4-5, pp. 237–246, 2002. View at Publisher · View at Google Scholar · View at Scopus
  79. X. Huo, Q. Liu, C. Wang et al., “Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin,” European Journal of Pharmaceutical Sciences, vol. 50, no. 3-4, pp. 420–428, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Li, L. Si, H. Pan et al., “Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: assessed in vitro by everted gut sac and in situ by improved intestinal perfusion,” International Journal of Pharmaceutics, vol. 403, no. 1-2, pp. 37–45, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. J. S. Woo, C. H. Lee, C. K. Shim, and S.-J. Hwang, “Enhanced oral bioavailability of paclitaxel by coadministration of the p-glycoprotein inhibitor KR30031,” Pharmaceutical Research, vol. 20, no. 1, pp. 24–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. A. M. Al-Mohizea, “Influence of intestinal efflux pumps on the absorption and transport of furosemide,” Saudi Pharmaceutical Journal, vol. 18, no. 2, pp. 97–101, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. H. L. Wong, X. Y. Wu, and R. Bendayan, “Nanotechnological advances for the delivery of CNS therapeutics,” Advanced Drug Delivery Reviews, vol. 64, no. 7, pp. 686–700, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Agarwal, N. Lariya, G. Saraogi, N. Dubey, H. Agrawal, and G. P. Agrawal, “Nanoparticles as novel carrier for brain delivery: a review,” Current Pharmaceutical Design, vol. 15, no. 8, pp. 917–925, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. M. D. Chavanpatil, A. Khdair, B. Gerard et al., “Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux,” Molecular Pharmaceutics, vol. 4, no. 5, pp. 730–738, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Fortuna, G. Alves, and A. Falcao, “In vitro and in vivo relevance of the p-glycoprotein probe substrates in drug discovery and development: focus on rhodamine 123, digoxin and talinolol,” Journal of Bioequivalence & Bioavailability, vol. 1, no. 2, 2011. View at Publisher · View at Google Scholar
  87. B. Mandal, H. Bhattacharjee, N. Mittal et al., “Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 9, no. 4, pp. 474–491, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Lamprecht and J.-P. Benoit, “Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition,” Journal of Controlled Release, vol. 112, no. 2, pp. 208–213, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. E. Roger, F. Lagarce, E. Garcion, and J.-P. Benoit, “Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells,” European Journal of Pharmaceutical Sciences, vol. 40, no. 5, pp. 422–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. C. W. Gan and S.-S. Feng, “Transferrin-conjugated nanoparticles of Poly(lactide)-d-α-Tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier,” Biomaterials, vol. 31, no. 30, pp. 7748–7757, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. F. Wang, D. Zhang, Q. Zhang et al., “Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance,” Biomaterials, vol. 32, no. 35, pp. 9444–9456, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Danson, D. Ferry, V. Alakhov et al., “Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer,” British Journal of Cancer, vol. 90, no. 11, pp. 2085–2091, 2004. View at Google Scholar · View at Scopus
  93. A. Béduneau, P. Saulnier, N. Anton et al., “Pegylated nanocapsules produced by an organic solvent-free method: evaluation of their stealth properties,” Pharmaceutical Research, vol. 23, no. 9, pp. 2190–2199, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. J. Huwyler, A. Cerletti, G. Fricker, A. N. Eberle, and J. Drewe, “By-passing of P-glycoprotein using immunoliposomes,” Journal of Drug Targeting, vol. 10, no. 1, pp. 73–79, 2002. View at Google Scholar
  95. R. Krishna, N. McIntosh, K. W. Riggs, and L. D. Mayer, “Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion,” Clinical Cancer Research, vol. 5, no. 10, pp. 2939–2947, 1999. View at Google Scholar · View at Scopus
  96. K. D. Lee, K. Hong, and D. Papahadjopoulos, “Recognition of liposomes by cells: In vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density,” Biochimica et Biophysica Acta—Biomembranes, vol. 1103, no. 2, pp. 185–197, 1992. View at Publisher · View at Google Scholar · View at Scopus
  97. E. R. Gillies and J. M. J. Fréchet, “Dendrimers and dendritic polymers in drug delivery,” Drug Discovery Today, vol. 10, no. 1, pp. 35–43, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Cui, Q. Xu, S. Gu, J. Shi, and X. Che, “PAMAM-drug complex for delivering anticancer drug across blood-brain barrier in-vitro and in-vivo,” African Journal of Pharmacy and Pharmacology, vol. 3, no. 5, pp. 227–233, 2009. View at Google Scholar · View at Scopus
  99. A. D'Emanuele, R. Jevprasesphant, J. Penny, and D. Attwood, “The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability,” Journal of Controlled Release, vol. 95, no. 3, pp. 447–453, 2004. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Svenson, “Dendrimers as versatile platform in drug delivery applications,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 71, no. 3, pp. 445–462, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. M. S. Muthu and S. Singh, “Poly (D, L-lactide) nanosuspensions of risperidone for parenteral delivery: formulation and in-vitro evaluation,” Current Drug Delivery, vol. 6, no. 1, pp. 62–68, 2009. View at Publisher · View at Google Scholar
  102. R. van der Meel, M. H. A. M. Fens, P. Vader, W. W. van Solinge, O. Eniola-Adefeso, and R. M. Schiffelers, “Extracellular vesicles as drug delivery systems: lessons from the liposome field,” Journal of Controlled Release, vol. 195, pp. 72–85, 2014. View at Publisher · View at Google Scholar
  103. S. M. van Dommelen, P. Vader, S. Lakhal et al., “Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery,” Journal of Controlled Release, vol. 161, no. 2, pp. 635–644, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. M. J. Haney, N. L. Klyachko, Y. Zhao et al., “Exosomes as drug delivery vehicles for Parkinson's disease therapy,” Journal of Controlled Release, vol. 207, pp. 18–30, 2015. View at Publisher · View at Google Scholar
  105. K. M. Mahar Doan, J. E. Humphreys, L. O. Webster et al., “Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs,” The Journal of Pharmacology and Experimental Therapeutics, vol. 303, no. 3, pp. 1029–1037, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. H. L. Wong, R. Bendayan, A. M. Rauth, and X. Y. Wu, “Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer,” Journal of Controlled Release, vol. 116, no. 3, pp. 275–284, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. A. Beloqui, M. Á. Solinís, A. R. Gascón, A. Del Pozo-Rodríguez, A. Des Rieux, and V. Préat, “Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier,” Journal of Controlled Release, vol. 166, no. 2, pp. 115–123, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. Y.-C. Kuo and H.-H. Chen, “Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier,” International Journal of Pharmaceutics, vol. 327, no. 1-2, pp. 160–169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. M. M. Yallapu, M. Jaggi, and S. C. Chauhan, “Design and engineering of nanogels for cancer treatment,” Drug Discovery Today, vol. 16, no. 9-10, pp. 457–463, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. N. Nasongkla, E. Bey, J. Ren et al., “Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems,” Nano Letters, vol. 6, pp. 2427–2430, 2006. View at Publisher · View at Google Scholar
  111. R. Mo, X. Jin, N. Li et al., “The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles,” Biomaterials, vol. 32, no. 20, pp. 4609–4620, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. S.-H. Kim and C.-C. Chu, “Synthesis and characterization of dextran-methacrylate hydrogels and structural study by SEM,” Journal of Biomedical Materials Research, vol. 49, no. 4, pp. 517–527, 2000. View at Publisher · View at Google Scholar · View at Scopus
  113. X. Zhuang, X. Tian, Y. Zheng et al., “Formulation and physicochemical characterisation of a novel self-microemulsifying delivery system as hydrotropic and solubilising agent for penfluridol,” Procedia Engineering, vol. 18, pp. 59–65, 2011, Proceedings of the 2nd SREE Conference on Chemical Engineering (CCE '11). View at Publisher · View at Google Scholar
  114. L. M. Negi, M. Tariq, and S. Talegaonkar, “Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation,” Colloids and Surfaces B: Biointerfaces, vol. 111, pp. 346–353, 2013. View at Publisher · View at Google Scholar · View at Scopus
  115. M. Estudante, J. G. Morais, G. Soveral, and L. Z. Benet, “Intestinal drug transporters: an overview,” Advanced Drug Delivery Reviews, vol. 65, no. 10, pp. 1340–1356, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. P. Blasi, S. Giovagnoli, A. Schoubben, M. Ricci, and C. Rossi, “Solid lipid nanoparticles for targeted brain drug delivery,” Advanced Drug Delivery Reviews, vol. 59, no. 6, pp. 454–477, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. R. Kumar and V. R. Sinha, “Thiomer: a potential carrier for therapeutic delivery,” Reactive & Functional Polymers, vol. 73, no. 8, pp. 1156–1166, 2013. View at Publisher · View at Google Scholar · View at Scopus